Gero Vita International and six related defendants are required to pay monetary judgments of $605,000 after settling Federal Trade Commission charges related to deceptive marketing practices, FTC reports June 8. The defendants, including dietary supplement direct marketer Almon Glenn Braswell, claimed their products could cure or treat illnesses and conditions such as diabetes, Alzheimer's disease and obesity, the agency says. FTC originally filed the complaint in May 2003 (1"The Tan Sheet" June 2, 2003, p. 13). The defendants are barred from making future misleading product claims in addition to the fines. The $605,000 settlement resulted from the suspension of a $30 mil. judgment based on the defendants' inability to pay. However, the defendants will have to pay the total $30 mil. if they misrepresented their financial condition or Braswell does business with any other defendant, FTC says...
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’
The EU product information for Novo Nordisk’s semaglutide medicines is to be updated to include non-arteritic anterior ischemic optic neuropathy as a side effect with a frequency of “very rare.”
The Pink Sheet explores how regulatory approvals for Leqembi differ around the world, and looks at what is coming next.
Experts from EUCOPE explain why the Council of the EU’s position on the proposed overhaul of the general pharmaceutical legislation could offer more predictability for companies than the commission’s initial offering.
